$559 Million is the total value of SPHERA FUNDS MANAGEMENT LTD.'s 128 reported holdings in Q2 2017. The portfolio turnover from Q1 2017 to Q2 2017 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ATHX | Exit | ATHERSYS INC | $0 | – | -773 | -100.0% | 0.00% | – |
| TRVN | Exit | TREVENA INC | $0 | – | -116,800 | -100.0% | -0.08% | – |
| ANAB | Exit | ANAPTYSBIO INC | $0 | – | -25,500 | -100.0% | -0.14% | – |
| GNMX | Exit | AEVI GENOMIC MEDICINE INC | $0 | – | -405,000 | -100.0% | -0.15% | – |
| RPRX | Exit | REPROS THERAPEUTICS INC | $0 | – | -778,800 | -100.0% | -0.18% | – |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -100,000 | -100.0% | -0.21% | – |
| FOMX | Exit | FOAMIX PHARMACEUTICALS LTD | $0 | – | -242,000 | -100.0% | -0.23% | – |
| RARX | Exit | RA PHARMACEUTICALS INC | $0 | – | -60,000 | -100.0% | -0.25% | – |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -40,000 | -100.0% | -0.28% | – |
| AAP | Exit | ADVANCE AUTO PARTS INC | $0 | – | -11,237 | -100.0% | -0.33% | – |
| ZYNE | Exit | ZYNERBA PHARMACEUTICALS INC | $0 | – | -100,000 | -100.0% | -0.39% | – |
| TBT | Exit | PROSHARES TR | $0 | – | -55,950 | -100.0% | -0.43% | – |
| FWP | Exit | FORWARD PHARMA A/Ssponsored adr | $0 | – | -108,023 | -100.0% | -0.46% | – |
| PRTK | Exit | PARATEK PHARMACEUTICALS INC | $0 | – | -140,000 | -100.0% | -0.53% | – |
| SBUX | Exit | STARBUCKS CORP | $0 | – | -46,631 | -100.0% | -0.53% | – |
| SLB | Exit | SCHLUMBERGER LTD | $0 | – | -34,911 | -100.0% | -0.53% | – |
| KITE | Exit | KITE PHARMA INC | $0 | – | -35,000 | -100.0% | -0.54% | – |
| AVXS | Exit | AVEXIS INC | $0 | – | -45,000 | -100.0% | -0.67% | – |
| HRTX | Exit | HERON THERAPEUTICS INC | $0 | – | -250,000 | -100.0% | -0.73% | – |
| Exit | TEVA PHARMACEUTICAL INDS LTDcall | $0 | – | -1,500 | -100.0% | -0.93% | – | |
| TEVA | Exit | TEVA PHARMACEUTICAL INDS LTDsponsored adr | $0 | – | -172,000 | -100.0% | -1.08% | – |
| Exit | ISHARES TRput | $0 | – | -500 | -100.0% | -1.36% | – | |
| HZNP | Exit | HORIZON PHARMA PLC | $0 | – | -480,000 | -100.0% | -1.39% | – |
| Exit | NEUROCRINE BIOSCIENCES INCput | $0 | – | -1,500 | -100.0% | -1.57% | – | |
| Exit | SPDR S&P 500 ETF TRput | $0 | – | -1,000 | -100.0% | -4.65% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-08-09
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| TEVA PHARMACEUTICAL-SP ADR | 36 | Q3 2023 | 8.4% |
| MERCK & CO INC NEW | 35 | Q3 2023 | 8.4% |
| NICE Systems Ltd | 27 | Q3 2023 | 4.4% |
| BIOGEN INC | 26 | Q3 2023 | 6.7% |
| AMICUS THERAPEUTICS INC | 26 | Q2 2022 | 4.3% |
| PFIZER INC | 25 | Q3 2023 | 9.2% |
| SAREPTA THERAPEUTICS INC | 25 | Q3 2023 | 3.2% |
| JOHNSON & JOHNSON | 24 | Q3 2023 | 8.0% |
| UNIQURE NV | 23 | Q3 2023 | 1.2% |
| SYNDAX PHARMACEUTICALS INC | 22 | Q3 2023 | 3.9% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Cyclacel Pharmaceuticals, Inc. | February 06, 2023 | 250,000 | 2.0% |
| Altimmune, Inc. | February 14, 2022 | 1,244,241 | 3.1% |
| Allot Ltd. | February 16, 2021 | 1,129,054 | 3.2% |
| Larimar Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Neos Therapeutics, Inc. | February 16, 2021 | ? | ? |
| Orgenesis Inc. | February 16, 2021 | 525,216 | 0.0% |
| Sio Gene Therapies Inc. | February 16, 2021 | ? | ? |
| X4 Pharmaceuticals, Inc | February 16, 2021 | 250,000 | 0.0% |
| Axovant Gene Therapies Ltd. | February 25, 2020 | 2,931,017 | 8.0% |
| Axovant Gene Therapies Ltd. | February 11, 2020 | 398,540 | 1.8% |
View SPHERA FUNDS MANAGEMENT LTD.'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR/A | 2024-02-15 |
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-08 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| SC 13G/A | 2024-02-05 |
| 13F-HR | 2023-11-14 |
| SC 13G | 2023-10-10 |
| SC 13G | 2023-08-30 |
View SPHERA FUNDS MANAGEMENT LTD.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.